Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2023 | BBB disruption impacts amyloid biomarker performance

Bruna Bellaver, PhD, University of Pittsburgh, Pittsburgh, PA, outlines an investigation into the impact of blood-brain-barrier (BBB) damage on the performance of plasma amyloid-β (Aβ) as a biomarker, explaining that those with BBB disruption have a stronger association between plasma and cerebrospinal fluid (CSF) Aβ levels. This suggests Aβ is crossing the BBB more freely. However, it was found that the same thing did not happen with p-tau181 or p-tau23: BBB function did not significantly impact the relationship between brain and plasma levels. These results link to the understanding that clearance of amyloid is mainly through the BBB, whereas p-tau clearance is poorly understood. These findings and those of previous studies suggest that there is not much clearance of p-tau via the BBB. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.